trending Market Intelligence /marketintelligence/en/news-insights/trending/dna_bf0uvg8ylqjkb84spa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Shire's rare-disease treatment granted Health Canada priority review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Shire's rare-disease treatment granted Health Canada priority review

Shire PLC's said Health Canada has completed screening and accepted the new drug submission under priority review for lanadelumab.

Lanadelumab, also known as SHP643, is an investigational treatment being evaluated for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema, a rare, genetic disorder characterized by recurrent episodes of severe swelling in the limbs, face, intestinal tract and airway.

Health Canada's priority review will shorten the assessment timeline for Lanadelumab to 180 days from 300 days.

Additionally, the European Medicines Agency validated its marketing authorization application for the drug. Shire said the validation confirms that the submission is sufficiently complete and an accelerated assessment of the potential therapy will begin.

In February, the EMA's Committee for Medicinal Products for Human Use granted an accelerated assessment for the drug, reducing the number of evaluation days required to 150 days from 210 days.

Shire said the filings are supported by data from its four clinical trials. In a phase 3 trial, called HELP, treatment with the drug resulted in an 87% reduction in the mean frequency of hereditary angioedema attacks compared to placebo.

Lanadelumab also received priority review from the U.S. Food and Drug Administration and priority review and orphan drug designation from the Therapeutic Goods Administration in Australia.

The FDA is expected to provide a decision by Aug. 26.

On March 28, Takeda Pharmaceutical Co. Ltd. said it was considering making a potential takeover bid for the Irish drugmaker, noting that the consideration is at a "preliminary and exploratory stage" and that the company has not reached out to Shire's board.